Stay updated with breaking news from Yaelc cohen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study. ....
Share Multiple myeloma (a type of blood cancer) patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science researchers, in collaboration with physicians from Tel Aviv Sourasky Medical Center (TASMC), have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma. Nature Medicine, may lead to a more informed, personalized treatment for these patients, and it paves the way to using this new technology for discovering additional disease targets in other cancers. ....